Energy Stock Goes Nuclear on Deregulation Buzz

AuthorAuthor

Ritesh Saxena & Adam Garcia
May 23, 2025

A consulting major is crashing after a weak forecast, an oil tanker operator is up on profit growth, and nuclear energy stock is surging as the White House signals support for next-gen reactor development and domestic fuel sourcing. Here’s what you need to know.

Smart Trade Picks (Sponsored)

High-probability trades start with proven patterns—and these 5 laminated cheatsheets make them easy to find and follow.

Each pattern has a backtested track record of up to 90% win rates.

Available now for free—limited quantity remaining.

*The profits and performance shown are not typical and you may lose money. We make no future earnings claims. All trades expressed are from historical, backtested data in order to demonstrate the potential of the system.

(By clicking the links above, you agree to receive future emails from us and our partners. You can opt out at any time. - Privacy Policy)

Futures 📈

What to Watch

Earnings:

  • None scheduled

Economic Reports:

  • Kansas City Fed President Jeff Schmid and St. Louis Fed President Alberto Musalem panel: 9:35 am

  • New Home Sales [April]: 10:00 am

  • Federal Reserve Governor Lisa Cook speech: 12:00 pm

Quick Gains (Sponsored)

Billions of dollars are already shifting thanks to President Trump’s policy shifts—fueling potential for outsized returns.

The Special Report, Presidential Profits: 6 Stocks to Ride Under The New Administration, identifies six stocks positioned for rapid gains.

Historic picks saw +196% and +277% returns post-2020 election; these new recommendations could climb even higher. Report access ends at midnight on May 8th.

Click Now To Lock In This Free Insight.

Consulting

Booz Allen Hamilton Shares Slide as Full-Year Forecast Disappoints Investors

Booz Allen Hamilton (NYSE:BAH) posted higher adjusted earnings in its fiscal fourth quarter but its shares are down 11% in premarket trading because its full-year forecast is below analyst projections.

For the quarter ending March 31, the consulting firm reported adjusted earnings of $1.61 per diluted share, up from $1.33 in the same period last year and in line with consensus estimates.

Revenue rose to $2.97 billion, marking a year-over-year increase from $2.77 billion, but came in slightly below the $3.03 billion analysts had anticipated.

Looking ahead to fiscal 2026, Booz Allen projected adjusted earnings between $6.20 and $6.55 per share. That guidance fell short of Wall Street’s average expectation of $6.88 per share.

The company also forecasted revenue between $12 billion and $12.5 billion, under the $12.82 billion projected by analysts.

Despite the strong year-over-year growth in both earnings and revenue for Q4, the subdued forward guidance is causing investors to view the stock negatively.

Shipping

Frontline Sees $33M Profit in Q1 Amid Tanker Market Stability

Frontline (NYSE:FRO) reported robust first-quarter earnings, highlighting improved profitability and strategic financial moves aimed at strengthening its balance sheet.

The oil tanker operator posted net income of $33.3 million for Q1 2025, alongside revenue of $427.9 million.

The company also declared a quarterly cash dividend of $0.18 per share. Strong average daily spot time charter equivalent earnings across its fleet contributed to the healthy bottom line.

In addition to its operational performance, Frontline announced the completion of several credit facility agreements aimed at refinancing outstanding debt.

These efforts are expected to reduce borrowing costs and bolster liquidity, positioning the company for greater financial flexibility moving forward.

Frontline is benefiting from favorable market dynamics, including limited fleet expansion and consistent global demand for crude oil transport.

The company continues to leverage its cost-efficient operating model and modern fleet to maintain competitive positioning in the global shipping industry.

Must-Watch Stocks (Sponsored)

Since 1988, a mathematical model has more than doubled the S&P 500 with powerful consistency.

A new Special Report highlights 7 of today’s strongest-ranked stocks—each positioned for performance over the next 30 days.

These rare finds represent the top of the Zacks Rank #1 Strong Buy list.

Fashion Retail

Buckle Sees Growth in Q1 Sales, Online Revenue Rises 4.5%

Buckle Inc. (NYSE:BKE) shares are up 5% in premarket trade due to modest gains in both earnings and revenue for its fiscal first quarter.

The fashion retailer reported net income of $35.2 million, or $0.70 per diluted share, for the quarter ending May 3, 2025, matching analyst expectations and slightly up from $0.69 per share in the same period a year ago. Wall Street estimates were $0.69 per share.

Net sales rose 3.7% year-over-year to $272.1 million, beating consensus estimates of $268.1 million. Comparable store sales were up 3%, while online sales increased 4.5% to $46.4 million, reflecting steady digital momentum.

The company continues to benefit from a loyal customer base and stable in-store traffic, despite broader retail headwinds tied to inflation and shifting consumer habits.

Buckle's performance was aided by its focus on exclusive private-label merchandise and a controlled inventory strategy, both of which contributed to maintaining margins.

Movers and Shakers

Centrus Energy Corp. [LEU] - Last Close: $93.17

Centrus Energy supplies enriched uranium fuel to the nuclear power industry. It has a strong track record of solid revenue growth and its shares are up 38% YTD.

LEU shares, among others in the nuclear power industry, are surging today in premarket trading following reports that President Trump is expected to sign executive orders easing regulations for new nuclear reactors and enhancing domestic fuel supply chains.

My Take: The executive order is a shot in the arm of a firm that’s already doing well for itself in a fast growing sector. Make sure you keep this stock on your watchlist.

Merus N.V. [MRUS] - Last Close: $15.53

Merus N.V. is a clinical-stage oncology company developing innovative bispecific and trispecific antibody therapeutics for cancer treatment.

While its net profitability has been declining in recent quarters, the stock is up today in premarket trading due to positive interim data from a phase 2 trial of its bispecific antibody.

My Take: This could be a big win for Merus, especially if the trial results for later phases corroborate the findings. However, as a clinical stage firm it remains a high risk stock for now. Keep it on your radar for updates.

Invivyd, Inc. [IVVD] - Last Close: $0.76

Invivyd is a biopharmaceutical company specializing in monoclonal antibodies for viral diseases, notably COVID-19.

It has seen strong positive revenue growth and improvement in net profitability in recent quarters, and the stock is up 60%+ YTD.

Its shares are climbing 8% today following the addition of PEMGARDA, its investigational monoclonal antibody to the NCCN Clinical Practice Guidelines for B-cell lymphomas.

My Take: Invvyid is a high-risk, high-reward opportunity, especially if PEMGARDA's adoption continues to grow. Make sure to keep tabs on the progress of this stock.

Future Gains (Sponsored)

Policy changes often spark market moves—and this latest investor report pinpoints 6 stocks aligned with current trends in Washington.

These companies could benefit from targeted spending, sector incentives, and regulatory tailwinds.

Previous picks from this strategy have surged triple digits. Now could be the time to act.

[Access the 6 Stock Picks Now]

(By submitting your email, you’ll also get a free Profit from the Pros membership, which highlights exclusive market updates and daily Strong Buy stocks. You can unsubscribe at any time.)

Everything Else

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.